BioLight Life Sciences Investments, which is the parent company of IOPtima, an Israeli life science company, signed a joint financing agreement with two Asia-based venture capital firms in order for them to invest $7.2 million into IOPtima. The new funding will be used to empower the global commercialization of its innovative IOPtimate system, which is used in the treatment of glaucoma.
